Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

By M. Mirza, B. Monk, J. Herrstedt, A. Oza, S. Mahner, A. Redondo, M. Fabbro, Jonathan A. Ledermann, D. Lorusso, I. Vergote and 18 more. New England Journal of Medicine, 2016

2,122 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/fca3e29f05d432bc0db0f1a240014589939ecb5c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pulmonary and Respiratory Medicine

Charles Swanton

In Reproductive Medicine

Citations in the corpus

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression (2017, positive): “More recently, another PARPi, niraparib, which was shown to significantly prolong the progression-free survival in ovarian cancer patients, received a fast track designation from the FDA for the treatment of patients with recurrent platinum-sensitive ovarian cancer (3).”
A decade of clinical development of PARP inhibitors in perspective (2019, background): “The phase III NOVA trial randomized 555 patients with platinum-sensitive recurrent HGOC to maintenance niraparib or placebo treatment after second or later line of platinumbased chemotherapy [28].”
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, methodology): “The NOVA study [38] utilised a different algorithm to identify potential HRD tumours and again found that, in patients who had responded to platinum in the relapse setting, the median PFS was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the p”
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance (2020, background): “However, an earlier study indicated that HRD status did not strongly correlate with tumor shrinkage following Veliparib treatment (Mirza et al., 2016; Hurley et al., 2019).”
Harnessing multimodal data integration to advance precision oncology (2021, background): “…processes melanoma 43 , EGFR in NSCLC 44 , ERBB2 (also known as HER2 ) in breast cancer 45 , IDH1 in acute myeloid leukaemia (AML) 46 , BRCA1 or BRCA2 in ovarian cancer 47 and prostate cancer 48 and even rare events such as neurotrophic tyrosine kinase (NTRK) fusions 49 for solid tumours.”
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019, result): “The latter group included patients with a somatic BRCA mutation or BRCA WT.38 In ARIEL3,37 rucaparib given after a response to platinum-based therapy showed similar results in patients with BRCA mutations (germline or somatic mutations) as well as in the whole ITT group with high-grade cancer.”
PARP Inhibitors: The First Synthetic Lethal Targeted Therapy (2017, background): “Overall, BRCAness-scar positive patients displayed longer PFS compared to BRCAness-scar negative patients, although the ultimate predictive value of this scar biomarker still requires clarification in larger phase 3 trials (54, 56).”
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2018, background): “These trials demonstrated improved outcome and therefore germline BRCA1 or BRCA2 mutations are tier I targets in these diseases [31, 32].”